The purpose of this study is to assess the efficacy and safety of ropinirole CR-RLS in the treatment of patients with Restless Legs Syndrome and associated sleep disturbance and period limb movements during sleep.

Inclusion criteria:

• provided written informed consent.
• Diagnosed with primary RLS using the International RLS Study Group Diagnostic Criteria with a total score of 20 or greater on the International RLS (IRLS) Rating Scale and significant sleep disturbance indicated on Item 4 of the IRLS rating scale.
• Have evening and nighttime symptoms of RLS, significant sleep impairment due to RLS symptoms, and symptoms requiring treatment prior to bedtime, but no earlier than 5:00PM.
• Sleep efficiency <85% OR Latency to persistent sleep >20 minutes.

Exclusion criteria:

• Secondary RLS
• Primary sleep disorder
• Have any medical conditions that may impact efficacy assessments or that may present a safety concern.
• Pregnant or lactating or women of child-bearing potential who are not practicing an acceptable method of birth control.
• Use of any prohibited medication.

Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.